Sol J Barer
CIK 1247015 · Executive Chairman · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CELG price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
124 DVORA HANEVI'A ST.
TEL AVIV
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TEVA | Director | 448,011 | $40.30 | $18.05M | $2.00M | 22 | 2026-06-08 |
| NexImmune, Inc. (NEXI) Delisted | Director | 150,234 | $0.00 | $15 | $1.73M | 13 | 2023-07-07 |
| CONTRAFECT Corp (CFRX) Delisted | Director | 1,020 | $0.05 | $51 | $49.6K | 8 | 2022-05-18 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Director | — | $2.93 | — | $0 | 3 | 2021-06-17 |
| GNMX | Director | 1,181,878 | $36.79 | $43.48M | $2.74M | 8 | 2019-12-09 |
| PDSB | Director | 678,075 | $1.10 | $749.3K | $0 | 1 | 2019-03-18 |
| EDGE | Director | 32,904 | $52.10 | $1.71M | $495.0K | 6 | 2018-08-15 |
| InspireMD, Inc. (NSPR.WS) Delisted | Director | — | $0.05 | — | $0 | 1 | 2016-12-08 |
| Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Director | 0 | — | — | $0 | 6 | 2016-11-30 |
| NSPR | Director | 2 | $0.45 | $1 | $2.31M | 22 | 2016-07-11 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Director | 45,000 | $14.49 | $652.0K | $167.6K | 10 | 2016-06-13 |
| CONTRAFECT Corp (CFRX.W) Delisted | Director | — | — | — | $0 | 1 | 2016-05-10 |
| Aevi Genomic Medicine, LLC (MDGN) Delisted | Director | — | — | — | $0 | 1 | 2016-04-19 |
| Aevi Genomic Medicine, LLC (MDGN.WS) Delisted | Director | 560,846 | — | — | $4.69M | 15 | 2015-10-08 |
| CONTRAFECT Corp (CFRX.Z) Delisted | Director | — | — | — | $0 | 2 | 2015-05-06 |
| CELGENE CORP /DE/ (CELGZ) Delisted | Director | 828,673 | — | — | -$4.32M | 2 | 2011-01-14 |
| CELGENE CORP /DE/ (CELG) Delisted | Executive Chairman | 1,621,082 | — | — | -$136.24M | 26 | 2010-10-14 |
Recent Filings · Page 6 of 16
157 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-06-07 | TEVA | Grant (A) | — | $0 | EDGAR |
| 2018-05-10 | CONTRAFECT Corp (CFRX) Delisted | — | — | $0 | EDGAR |
| 2017-10-18 | GNMX | Buy (P) | +421,032 | $530.5K | EDGAR |
| 2017-08-10 | GNMX | Grant (A) | — | $0 | EDGAR |
| 2017-07-26 | CONTRAFECT Corp (CFRX) Delisted | Buy (P) | +40,000 | $49.6K | EDGAR |
| 2017-07-10 | EDGE | Exer (X) | +12,530 | $29.9K | EDGAR |
| 2017-06-21 | EDGE | Grant (A) | — | $0 | EDGAR |
| 2017-05-04 | CONTRAFECT Corp (CFRX) Delisted | — | — | $0 | EDGAR |
| 2017-05-01 | GNMX | Buy (P) | +100,000 | $156.7K | EDGAR |
| 2017-04-27 | GNMX | Buy (P) | +100,000 | $154.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.